For research use only. Not for therapeutic Use.
Sulbactam（Cat No.:A001207）, also known as CP 45899, is a β-lactamase inhibitor. This drug is given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotics. Sulbactam is an irreversible inhibitor of β-lactamase; it binds to the enzyme and does not allow it to degrade the antibiotic.Sulbactam is able to inhibit the most common forms of β-lactamase but is not able to interact with the AmpC cephalosporinase. Thus, it confers little protection against bacteria such as Pseudomonas aeruginosa, Citrobacter, Enterobacter, and Serratia, which often express this gene.
| Catalog Number | A001207 |
| CAS Number | 68373-14-8 |
| Synonyms | NA |
| Molecular Formula | C8H11NO5S |
| Purity | 98% |
| Target | beta-lactamase |
| Target Protein | P05364 |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IUPAC Name | (2S,5R)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| InChI | InChI=1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1 |
| InChIKey | FKENQMMABCRJMK-RITPCOANSA-N |
| SMILES | CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C |
| Reference | </br>1:Genetic and functional characterization of <i>bla</i><sub>CTX-M-199</sub>, a novel tazobactam and sulbactam resistance-encoding gene located in a conjugative <i>mcr-1</i>-bearing IncI2 plasmid. Cai J, Cheng Q, Shen Y, Gu D, Fang Y, Chan EW, Chen S.Antimicrob Agents Chemother. 2017 May 8. pii: AAC.00562-17. doi: 10.1128/AAC.00562-17. [Epub ahead of print] PMID: 28483954 </br>2:Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin sulbactam in primary hospital. Sun L, Wang X, Li Z.Br J Neurosurg. 2017 Apr 21:1-4. doi: 10.1080/02688697.2017.1319907. [Epub ahead of print] PMID: 28431478 </br>3:Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study. Chaudhary M, Mir MA, Ayub SG; Protocol 06 Group..Braz J Infect Dis. 2017 Apr 1. pii: S1413-8670(16)30463-9. doi: 10.1016/j.bjid.2017.02.007. [Epub ahead of print] PMID: 28376315 Free Article</br>4:Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014). Pfaller MA, Flamm RK, Duncan LR, Mendes RE, Jones RN, Sader HS.Diagn Microbiol Infect Dis. 2017 Jun;88(2):177-183. doi: 10.1016/j.diagmicrobio.2017.02.020. Epub 2017 Mar 6. PMID: 28341098 </br>5:An Evaluation of Selected Indications and Appropriateness of Ampicillin/Sulbactam, an Unrestricted Antimicrobial, at a Single Center. McCoy D, Sebti R, Kuyumjian AG.P T. 2017 Mar;42(3):189-194. PMID: 28250702 Free PMC Article</br>6:Spectroscopy analysis and molecular dynamics studies on the binding of penicillin V and sulbactam to beta-lactamase II from Bacillus cereus. Shi P, Qiao P, Zhang Y, Li S, Feng X, Bian L.J Pharm Biomed Anal. 2017 May 10;138:206-214. doi: 10.1016/j.jpba.2017.02.017. Epub 2017 Feb 11. PMID: 28219797 </br>7:Ampicillin/sulbactam-induced Kounis syndrome with cardiogenic shock. Kounis NG, Koniari I.Anatol J Cardiol. 2017 Feb;17(2):154-155. doi: 10.14744/AnatolJCardiol.2016.7612. No abstract available. PMID: 28209929 Free Article</br>8:Management of Pneumonia and Blood Stream Infections with New Antibiotic Adjuvant Entity (Ceftriaxone + Sulbactam + Disodium Edetate)- A Novel Way to Spare Carbapenems. Shameem M, Mir MA.J Clin Diagn Res. 2016 Dec;10(12):LC23-LC27. doi: 10.7860/JCDR/2016/20904.9014. Epub 2016 Dec 1. PMID: 28208889 Free PMC Article</br>9:Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: A systematic review and meta-analysis. Chen H, Liu Q, Chen Z, Li C.J Infect Chemother. 2017 May;23(5):278-285. doi: 10.1016/j.jiac.2017.01.005. Epub 2017 Feb 13. PMID: 28202329 </br>10:Corrigendum to /Comparison of commonly used antimicrobial susceptibility testing methods for evaluating susceptibilities of clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli to cefoperazone-sulbactam/ [J Microbiol Immunol Infect (2015)] pii: S1684-1182(15)00847-6. [Epub ahead of print]. Jean SS, Liao CH, Sheng WH, Lee WS, Hsueh PR.J Microbiol Immunol Infect. 2017 Feb 8. pii: S1684-1182(17)30003-8. doi: 10.1016/j.jmii.2017.01.003. [Epub ahead of print] No abstract available. PMID: 28189523 Free Article |
